These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27489070)

  • 21. Mechanism of action of ketamine.
    Stahl SM
    CNS Spectr; 2013 Aug; 18(4):171-4. PubMed ID: 23866089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 23. [Ketamine for treatment of acute depression].
    Hjerrild S; Bjerre J; Pedersen RH; Videbech P
    Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated S-ketamine infusions in therapy resistant depression: a case series.
    Segmiller F; Rüther T; Linhardt A; Padberg F; Berger M; Pogarell O; Möller HJ; Kohler C; Schüle C
    J Clin Pharmacol; 2013 Sep; 53(9):996-8. PubMed ID: 23893490
    [No Abstract]   [Full Text] [Related]  

  • 25. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.
    Thomas RK; Baker G; Lind J; Dursun S
    J Psychopharmacol; 2018 Oct; 32(10):1110-1117. PubMed ID: 30182797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NMDA antagonist treatment of depression.
    Williams NR; Schatzberg AF
    Curr Opin Neurobiol; 2016 Feb; 36():112-7. PubMed ID: 26687375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
    Wan LB; Levitch CF; Perez AM; Brallier JW; Iosifescu DV; Chang LC; Foulkes A; Mathew SJ; Charney DS; Murrough JW
    J Clin Psychiatry; 2015 Mar; 76(3):247-52. PubMed ID: 25271445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Esketamine nasal spray (Spravato) for treatment-resistant depression.
    Med Lett Drugs Ther; 2019 Apr; 61(1569):54-57. PubMed ID: 31169797
    [No Abstract]   [Full Text] [Related]  

  • 29. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
    Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
    Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression.
    Correia-Melo FS; Silva SS; Araújo-de-Freitas L; Quarantini LC
    Braz J Psychiatry; 2017; 39(2):188-189. PubMed ID: 28591272
    [No Abstract]   [Full Text] [Related]  

  • 31. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
    Szarmach J; Cubała WJ; Włodarczyk A; Wiglusz MS
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):585-590. PubMed ID: 31488795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
    Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Cheng CM; Su TP
    CNS Spectr; 2021 Aug; 26(4):362-367. PubMed ID: 32419678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
    Banov MD; Landrum RE; Moore MB; Szabo ST
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system.
    Włodarczyk A; Cubała WJ; Szarmach J; Małyszko A; Wiglusz MS
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):530-533. PubMed ID: 31488786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy].
    Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
    Psychiatr Pol; 2014; 48(1):49-58. PubMed ID: 24946434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study.
    Domany Y; Bleich-Cohen M; Tarrasch R; Meidan R; Litvak-Lazar O; Stoppleman N; Schreiber S; Bloch M; Hendler T; Sharon H
    Br J Psychiatry; 2019 Jan; 214(1):20-26. PubMed ID: 30246667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
    Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression].
    Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
    Psychiatr Pol; 2012; 46(2):283-94. PubMed ID: 23214398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time until relapse after augmentation with single-dose ketamine in treatment-resistant depression.
    Pérez-Esparza R; Corona T; Ruiz-García RG; Oñate-Cadena N; de la Fuente-Sandoval C; Ramírez-Bermúdez J
    Psychiatry Clin Neurosci; 2018 Aug; 72(8):623. PubMed ID: 29744959
    [No Abstract]   [Full Text] [Related]  

  • 40. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
    De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
    Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.